Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CDK9: a promising therapeutic opportunity in prostate cancer

31 Aug 2016

Abstract excerpt

Cyclin-dependent kinase 9 (CDK9) is a key transcriptional regulator and a lucrative target for cancer treatment. Targeting CDK9 can effectively confine the hyperactivity of androgen receptor and the constitutive expression of anti-apoptotic proteins; both being main causes of prostate cancer (PCa) development and progression. In castrate-resistant PCa, traditional therapies that only target androgen receptor (AR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27582311
DOI: 10.1530/erc-16-0299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CDK9: a promising therapeutic opportunity in prostate cancerPMID 27582311Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.Semantic proximity Read ↗

Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancerSemantic proximity Read ↗

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read ↗

CDK9: A key player in cancer and other diseasesSemantic proximity Read ↗

Androgen signaling and its interactions with other signaling pathways in prostate cancerSemantic proximity Read ↗

CDK9 as an Appealing Target for Therapeutic InterventionsSemantic proximity Read ↗

CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cellsSemantic proximity Read ↗

AR Signaling and the PI3K Pathway in Prostate CancerSemantic proximity Read ↗

Loss and revival of androgen receptor signaling in advanced prostate cancerSemantic proximity Read ↗

CDK19 and CDK8 Mediator kinases drive androgen-independent <i>in vivo</i> growth of castration-resistant prostate cancerSemantic proximity Read ↗

Addressing Transcriptional Dysregulation in Cancer through CDK9 InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.